Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-05-12
Original SEC Filing: Click here
Webplus: SKBI/20100512/8-K/2_EX-99.1/000.htm SEC Original: v184608_ex99-1.htm
SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THEMPANYS PRODUCT LINES The new dosage forms projected to generate $5 million inditional revenue by fiscal 2011 XI’AN, CHINA May 12, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) (“Skystar” or the “Company”), The product testing process will ensure that the new dosage forms willhere to good manufacturing
Webplus: SKBI/20100512/8-K/1/000.htm SEC Original: v184608_8k.htm
FORM 8-K CURRENT REPORTte of report (Date of earliest event reported): May 12, 2010YSTAR BIO-PHARMACEUTICALMPANY Nevada 001-34394 33-0901534 (State or other jurisdiction oforporation or organization) (Commission File No.) (IRS Employer Identification No.) Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian, Shaanxi Province, P.R. China
Company Information:
Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-05-12CIK: 0001076939, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
RM 10601, JIEZUO PLAZA, NO. 4, FENGHUI ROAD SOUTH, GAOXIN DISTRICT
XIAN PROVINCE
-
- Forum
- Topics
- Last Post
Leave A Comment
You must be logged in to post a comment.